None

CHMP recommends more restrictions for cilostazol

More restrictions should be placed on the use of cilostazol so that only patients for whom the benefit outweighs the risks are prescribed the drug, the Committee on Medicinal Products for Human Use (...

EMA Recommends Restricting Cilostazol Use for PAD

The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual a...

EMA pushes for clampdown on cilostazol drugs

The European Medicines Agency's Committee on Medicinal Products for Human Use ( CHMP) has recommended restricting the use of cilostazol-containing medicines after concluding in a review that their be...

Cilostazol reduces restenosis after angioplasty in critical limb ischemia

The quinolinone derivative cilostazol may be associated with reduced restenosis, reocclusion, and clinically driven target lesion revascularization 3 months after infrapopliteal angioplasty, researche...

European Medicines Agency recommends restricting use of cilostazol-containing medicines

The European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol-containing medicines in the treatment of intermittent claudication...

EMA recommends restricting use of cilostazol-containing medicines

The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol-containing medicines in the treatment of intermittent claudication - a c...

News and press releases: European Medicines Agency recommends restricting use of cilostazol-containing medicines

The European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol-containing medicines in the treatment of intermittent claudication –...

Cilostazol-containing medicines regulatory update

Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects.

Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean he...

The effect of cilostazol on the expression of matrix metalloproteinase-1 and type I procollagen in ultraviolet-irradiated human dermal fibroblasts.

Cilostazol is a selective inhibitor of type III phosphodiesterase that inhibits platelet aggregation. Cilostazol is a useful vasodilator, antithrombotic, and cardiotonic agent. Ultraviolet B (UVB) irr...

Periprocedural Cilostazol Treatment and Restenosis after Carotid Artery Stenting: The Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).

Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. We investigated whether periprocedural...

Inhibitory Effects of Cilostazol on Proliferation of Vascular Smooth Muscle Cells (VSMCs) Through Suppression of the ERK1/2 Pathway.

Aim: The abnormal proliferation of vascular smooth muscle cells (VSMCs) in arterial walls is an important pathogenic factor of vascular disorders such as atherosclerosis and restenosis after angioplas...

Comparison of antiplatelet and antithrombotic therapy for secondary prevention of ischemic stroke in patients with peripheral artery disease.

Background: A limited number of studies have assessed the benefit and risk among the different antiplatelet and antithrombotic therapies in patient with stroke and peripheral artery disease (PAD). W...